Influenza Vaccine Market is projected to grow to US$ 13.75 billion by 2032 | Sanofi, GSK plc, SINOVAC, Zydus Cadila Healthcare, CSL, Viatris Inc

The Influenza Vaccine market was valued at US$ 8.41 billion in 2024 and is projected to grow to approximately US$ 13.75 billion by 2032, with a compound annual growth rate (CAGR) of 6.5% during the forecast period from 2025 to 2032.

Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/influenza-vaccines-market?sg

Influenza Vaccine Market Key Drivers:
• Rising Global Influenza Burden
The seasonal nature of influenza, with millions affected annually, creates consistent demand for vaccines. The risk of pandemic strains emerging further reinforces the need for mass immunization programs worldwide.

• Government Immunization Initiatives
National health agencies and global organizations actively promote influenza vaccination, particularly for high-risk groups. Public sector procurement and vaccination mandates in schools, hospitals, and aged-care facilities are major growth contributors.

• Advancements in Vaccine Technology
Development of quadrivalent, cell-based, and recombinant influenza vaccines is improving efficacy and production timelines. These innovations are expanding product offerings and strengthening market competitiveness.

• Aging Population and Comorbidities
The growing elderly population, which is more susceptible to flu complications, is driving demand. Additionally, people with chronic conditions such as diabetes or cardiovascular disease represent a key target demographic.

• Increasing Awareness and Education Campaigns
Public health messaging and media campaigns highlighting the importance of annual flu vaccination are influencing consumer behavior, especially in urban populations.

Influenza Vaccines Market Segments:
• By Product Type (Inactivated, Live Attenuated)
• By Category (Quadrivalent, Trivalent)
• By Route of Administration (Injection, Nasal Spray)
• By Age Group (Pediatric, Adults)
• By End-User (Hospitals, Specialty Clinics, Others)

Make an Enquiry for purchasing this Report @ https://www.datamintelligence.com/enquiry/influenza-vaccines-market?sg

Influenza Vaccines Market: Geographical Share:

• North America
North America holds the largest share of the global influenza vaccines market, driven by strong government immunization programs, high healthcare spending, and robust awareness campaigns. The U.S. CDC's annual flu vaccination recommendations, coupled with significant investments in vaccine R&D and pandemic preparedness, further boost regional demand.

• Europe
Europe follows closely due to widespread vaccination coverage, strong public health infrastructure, and supportive regulatory policies. Countries like the UK, Germany, and France maintain high seasonal influenza vaccination rates among vulnerable populations such as the elderly and those with chronic illnesses.

• Asia-Pacific
The Asia-Pacific region is experiencing rapid growth, fueled by increasing population density, rising healthcare awareness, and improved access to vaccines. Government-led immunization drives in countries like China, India, and Japan are expanding market penetration, especially amid concerns over potential outbreaks and zoonotic influenza strains.

• Latin America and Middle East & Africa
These regions are witnessing moderate growth. Efforts by public health agencies and international collaborations are enhancing access to flu vaccines. However, limited infrastructure and variable vaccine coverage remain key challenges in certain countries.

Influenza Vaccine Market Key Players: Sanofi, GSK plc., Pfizer Inc., AstraZeneca, CSL, Viatris Inc. (Mylan), Bharat Biotech., SINOVAC, Zydus Cadila Healthcare Limited, and Serum Institute of India Pvt. Ltd.

Request for FREE Trial Access: https://www.datamintelligence.com/reports-subscription?sg

New product launches & approvals:

FluMist nasal spray, produced by AstraZeneca/MedImmune, received FDA approval in September 2024 for self‐ or caregiver‐administration at home for people up to age 49. Distribution via online pharmacies begins fall 2025.
Arcturus Therapeutics initiated a Phase 1 trial (called LUNAR‐H5N1 or ARCT‐2304) for its self‐amplifying mRNA H5N1 pandemic influenza vaccine. First participants were dosed in December 2024; interim data is expected in the second half of 2025.

Major M&A deals and acquisitions:

In July 2025, Sanofi announced acquisition of UK bioteche firm Vicebio for up to US $1.6 billion. The deal brings early-stage vaccine candidates (including combination RSV/HMPV formulations) and "molecular clamp" technology that supports standard‐refrigeration storage. Completion is expected in Q4 2025.

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.